Business Wire1d
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...
Nature1y
The immunological relay race: B cells take antigen by synapse
A number of pathogens can initiate the mannan-binding lectin and alternative pathways of complement activation. The classical and alternative pathways of complement activation all tag antigens ...
Business Wire26d
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
About Narsoplimab Narsoplimab, also known as “OMS721,” is an investigational fully human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), a novel pro ...